Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Rett Syndrome Research Trust Awards $1.1 Million to Emerald Innovations to Develop Novel Invisible Biosensor for Objective Measures of Rett Symptoms


News provided by

Rett Syndrome Research Trust

Feb 21, 2023, 07:30 ET

Share this article

Share toX

Share this article

Share toX


We are very excited to advance the Emerald device in this rare disease to facilitate better patient management and support the assessment of therapeutics in development.

Post this

The Rett Syndrome Research Trust (RSRT) is excited to announce a $1.1 million dollar research award to Dina Katabi, PhD, and her team at Emerald Innovations. The funding will enable Dr. Katabi and Emerald Innovations to continue developing cutting-edge technology to directly and objectively assess symptoms of irregular breathing, sleep disruptions, and movement in individuals with Rett syndrome. The new study builds upon pilot results that demonstrated Emerald's feasibility to assess Rett syndrome symptoms at home, capturing significant disruptions in sleep and breathing over a four-week period — all without touching the patient.

TRUMBULL, Ct., Feb. 21, 2023 Feb.21, 2023 -- The Rett Syndrome Research Trust (RSRT) is excited to announce a $1.1 million dollar research award to Dina Katabi, PhD, and her team at Emerald Innovations. The funding will enable Dr. Katabi and Emerald Innovations to continue developing cutting-edge technology to directly and objectively assess symptoms of irregular breathing, sleep disruptions, and movement in individuals with Rett syndrome. The new study builds upon pilot results that demonstrated Emerald's feasibility to assess Rett syndrome symptoms at home, capturing significant disruptions in sleep and breathing over a four-week period — all without touching the patient.

Emerald technology is invisible, meaning it assesses a patient's physiology when they are in the vicinity of the device, keeping it in a distinct class from wearable technologies that require constant contact. Emerald also preserves privacy — it does not use cameras or microphones, or capture audio or video. Instead, it uses artificial intelligence (AI) to measure movements, sleep, and vital signs from very low power radio waves in the environment, advancing a new era to collect continuous data at home. It allows families and their loved ones with Rett to go about their daily lives while enabling detailed characterization of various symptoms to generate highly specific representative datasets. Alba Tull, a member of RSRT's Board of Trustees, investor, and philanthropist generously donated $500,000 to support the upcoming study for Rett syndrome.

Dr. Katabi is the president and co-founder of Emerald Innovations, a spinout from the Massachusetts Institute of Technology (MIT), where Dr. Katabi serves as the inaugural Thuan and Nicole Pham Professor in the Department of Engineering and Computer Science, director of the MIT Center for Wireless Networks and Mobile Computing, and leader of the Networks at MIT Research Group in the Computer Science and Artificial Intelligence Lab. She is a member of the National Academy of Engineering as well as the American Academy for Arts and Sciences, a MacArthur Fellow, and the recipient of various prestigious awards, including the Sloan Research Fellowship and the ACM Computing Prize. In 2015, she presented Emerald to President Obama at White House Demo Day, which focused on breakthroughs in technology.

"We are very excited to advance the Emerald device in this rare disease to facilitate better patient management and support the assessment of therapeutics in development," said Dr. Katabi. "The breathing and sleep patterns we observed in Rett individuals are quite disrupted, and we are confident that Emerald's ability to systematically and objectively assess symptoms unobtrusively at home will improve the lives of patients and their families."

Dr. Katabi's most recent publications, in Science Translational Medicine and Nature Medicine, demonstrate the power of the technology in Parkinson's disease. Emerald was able to predict risk of diagnosis, and more sensitively detect prognosis and medication effects than current standards. She hopes insights from Emerald will similarly benefit Rett syndrome.

Members of RSRT's Biomarker Consortium, consisting of subject matter experts and representatives from biopharmaceutical companies developing genetic medicines for Rett, provided constructive feedback on the study design and will have early access to the data. The Emerald sensor is currently being utilized in drug development for Alzheimer's disease, Parkinson's disease, and several immune diseases. Validation of the device in the upcoming Rett study will make it easier to support Rett clinical development efforts as well.

"The Emerald provides direct, objective measures of symptoms captured continuously over days, weeks, months, or longer, generating significantly richer data in shorter timeframes than can be obtained in traditional in-clinic studies," said Jana von Hehn, PhD, RSRT's chief scientific officer, who will oversee study operations. "We are excited to continue this important work with Emerald, guided by our Biomarker Consortium and FDA advice, to facilitate more efficient clinical trials and truly effective therapeutics."

ABOUT THE RETT SYNDROME RESEARCH TRUST

RSRT is a nonprofit organization with a highly personal and urgent mission: achieving a cure for Rett syndrome and related disorders caused by defects in the MECP2 gene. Since its founding in 2008, RSRT has awarded $66 million, more than any other Rett organization in the world, to leading scientists pursuing targeted research on Rett. RSRT funds and spearheads global scientific and clinical activities advancing the most promising curative approaches. To date, every biopharmaceutical company pursuing a cure for Rett syndrome is doing so because they leveraged discoveries and resources incubated with RSRT funding. To learn more, please visit http://www.reverserett.org.

ABOUT EMERALD INNOVATIONS, Inc.

Emerald Innovations, Inc. is a spin-out from MIT that is transforming digital health monitoring from wearables to invisibles. It is based on an artificial intelligence-powered sensor that continuously measures movements, vital signs, sleep, and behavior by analyzing the wireless signals bouncing in the environment. Emerald's passive technology eliminates the need for patients to wear devices on their body. Emerald is being used by the world's largest pharma and biotech companies, and leading disease research foundations in clinical trials in all phases, and in a variety of therapeutic areas — neurology, immunology, and rare diseases. For more information, please visit https://www.emeraldinno.com/.

Media Contact

Emily Dulcan, Rett Syndrome Research Trust, 1 720.773.2196, [email protected]

SOURCE Rett Syndrome Research Trust

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.